Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26030978 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Daisuke Taguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan. Hauptthemen laut MEDLINE: Canagliflozin, Cholangiocarcinoma, Bile Duct Neoplasms, Acrylamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cholangiocarcinoma-associated mortality has been increasing over the past decade. The sodium-glucose cotransporter 2 inhibitor, canagliflozin, has demonstrated anti-tumor effects against several types of cancers; however, studies examining its potential impact on cholangiocarcinoma are lacking. This study investigated the anti-tumor effects of canagliflozin on cholangiocarcinoma and the effects of nicotinamide adenine dinucleotide (NAD)+ salvage pathway activation and sirtuin 1 on tumor growth. We evaluated cell proliferation and gene expression in several cholangiocarcinoma cell lines and analyzed the effects of canagliflozin on cell proliferation, apoptosis, and migration. Canagliflozin treatment decreased the viability of cholangiocarcinoma cells in a concentration-dependent manner but increased the viability at low concentrations in several cell lines. At high concentrations, canagliflozin arrested the cell cycle checkpoint in the G0/G1 phase. In contrast, at low concentrations, it increased the proportion of cells in the S phase. Canagliflozin also reduced the migratory ability of cholangiocarcinoma cells in a concentration-dependent manner. Canagliflozin treatment upregulated nicotinamide phosphoribosyltransferase (NAMPT), NAD+, and sirtuin 1 in cholangiocarcinoma and activated the NAD+ salvage pathway. The growth-inhibitory effect of canagliflozin was enhanced when combined with an NAMPT inhibitor. Canagliflozin inhibits cholangiocarcinoma cell growth and migration and its anti-tumor effect is enhanced when combined with an NAMPT inhibitor. However, further investigation is required because of its potential tumor growth-promoting effect through the activation of the NAD+ salvage pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
ORCID-Profile: Daisuke Taguchi, Yohei Shirakami, Hiroyasu Sakai, Takao Miwa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Taguchi, D., Shirakami, Y., Sakai, H., Minowa, D., Miwa, T., Maeda, T., Kubota, M., Imai, K., Ibuka, T., & Shimizu, M. (2025). Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26030978
Vancouver
Taguchi D, Shirakami Y, Sakai H, Minowa D, Miwa T, Maeda T, et al. Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26030978
BibTeX
@article{Taguchi2025,
author = {Taguchi, Daisuke and Shirakami, Yohei and Sakai, Hiroyasu and Minowa, Daisuke and Miwa, Takao and Maeda, Toshihide and Kubota, Masaya and Imai, Kenji and Ibuka, Takashi and Shimizu, Masahito},
title = {Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26030978}
}
EUVIMED